Shiyu Capital
VC Fund
Beijing, China
Shiyu Capital is a VC fund in Beijing focused on Health Care and Biotechnology. Shenzhen Shiyu Investment Management Co.,Ltd.(SHIYU or the Company )is a professional equity investment and asset management institution, focusing on equity investment in pharmaceutical and healthcare industry, asset allocation and wealth management.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $473M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Shiyu Capital invests in
Stages Shiyu Capital invests in
Countries Shiyu Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Zhizhong Li
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 10 (53%)
- Biotechnology 6 (32%)
- Pharmaceutical 5 (26%)
- Medical 4 (21%)
- Therapeutics 3 (16%)
Stage
- Series A 8 (42%)
- Series B 3 (16%)
- Seed 2 (11%)
- Angel 1 (5%)
- Series C 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Zhizhong Li
Chief Science Officer
|
Chief Science Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hainan Zhongle
|
Hainan Zhongle is a Yuanverse technology R&D and innovation service provider. It focuses on Yuanverse fundamental technologies, such as virtual reality, augmented reality, artificial intelligence, blockchain, and others. | $694.7K / Seed / Feb 28, 2024 | |
OnQuality Pharmaceuticals
|
OnQuality Pharmaceuticals offers trials to assess the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients. | $20M / Series A / Mar 31, 2021 | |
QnQuality Pharmaceuticals
|
QnQuality Pharmaceuticals is a new drug research and development specialist for cancer-assisted therapeutics, focusing on unmet clinical needs in the field of oncology supportive care, and is committed to helping cancer patients around the world improve their quality of life. Kuankuo Pharmaceutical has established a rich R&D pipeline coveringsix indications and a research and development team in China and the United States ( | $20M / Series A / Mar 31, 2021 | |
Biotheus
|
Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies. | Series B / Mar 03, 2021 | |
|
Biotheus
|
Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies. | $100M / Series D / Mar 02, 2021 | |
WuXi Diagnostics
|
WuXi Diagnostics builds an innovative model that enables diagnostic product innovation, generates clinical insights, and benefits the health of mankind through precision diagnosis and treatment. | $150M / Series B / Feb 23, 2021 | |
Novast
|
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel.Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in Chinaselling pharmaceutical products into US local market.Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology. | $62.2M / Venture - Series Unknown / Jan 29, 2021 | |
CARsgen Therapeutics
|
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, bycompleting World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. | $186M / Series C / Nov 02, 2020 | |
|
Novast
|
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel.Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in Chinaselling pharmaceutical products into US local market.Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology. | $141.7M / May 12, 2020 | |
|
Novast
|
Novast is focused on the research, development and manufacture of value-added generic drugs with release control and other dosage types, and sells them into US pharmaceutical market cooperating with US leading channel.Cooperating with US sales channels and original development enterprises, it is the first pharmaceutical enterprise in Chinaselling pharmaceutical products into US local market.Novast Pharmaceutical Company owns cGMP manufacturing facilities covering18, 000 square meters, and its management team has experiences of applying more than 100 generic drug patents in U.S., and many years of working experience in U.S. Novast also independently researches and develops multiple drug-delivery and dosage type technology. | $141.4M / Series E / May 08, 2020 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shiyu Capital invest in?
Shiyu Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shiyu Capital?
Public channels for Shiyu Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shiyu Capital?
The team at Shiyu Capital includes Zhizhong Li (Chief Science Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
